Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

X4 Pharmaceuticals Inc (XFOR)

X4 Pharmaceuticals Inc (XFOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

XFOR : 0.3380 (-8.25%)
X4 Pharmaceuticals: Q3 Earnings Snapshot

X4 Pharmaceuticals: Q3 Earnings Snapshot

XFOR : 0.3380 (-8.25%)
X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

XFOR : 0.3380 (-8.25%)
X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

XFOR : 0.3380 (-8.25%)
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XFOR : 0.3380 (-8.25%)
X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

XFOR : 0.3380 (-8.25%)
X4 Pharmaceuticals: Q2 Earnings Snapshot

X4 Pharmaceuticals: Q2 Earnings Snapshot

XFOR : 0.3380 (-8.25%)
3 Microcap Stocks With Big Breakout Potential

Analysts see substantial potential for price appreciation in these three microcap stocks from their current levels.

BTBT : 4.44 (+11.28%)
^BTCUSD : 98,274.09 (-1.00%)
^ETHUSD : 3,328.888 (+0.38%)
RGTI : 1.7400 (+17.57%)
XFOR : 0.3380 (-8.25%)
Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has...

PHAR : 7.53 (-2.96%)
KA : 0.5746 (-30.69%)
APRE : 2.88 (-1.46%)
XFOR : 0.3380 (-8.25%)
Scorpion Therapeutics Announces Formation of World-Class Clinical Scientific Advisory Board

Scorpion Therapeutics, Inc. (“Scorpion Therapeutics”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced the formation...

XFOR : 0.3380 (-8.25%)

Barchart Exclusives

3 High-Yielding Dividend Kings to Boost Your Income in 2025 and Beyond
These three high-quality companies are currently on sale, offering elevated yields that appeal to dividend growth investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar